NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

ELVN

Enliven Therapeutics Inc

May 09 • 04:00PM ET

18.42

Dollar change -0.21
Percentage change -1.13	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX ALNY IONS BMRN INCY NBIX PRTA EXEL ONC

| Held by: VTI IWM VXF IWO IBB VTWO SCHA IWC IHE VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.90	Insider Own	35.30%	Shs Outstand	48.94M	Perf Week	-10.19%
Market Cap	903.80M	Forward P/E	-	EPS next Y	-2.54	Insider Trans	-0.75%	Shs Float	31.94M	Perf Month	11.50%
Income	-89.02M	PEG	-	EPS next Q	-0.50	Inst Own	72.83%	Short Float	23.30%	Perf Quarter	-16.27%
Sales	0.00M	P/S	-	EPS this Y	-16.22%	Inst Trans	7.07%	Short Ratio	27.34	Perf Half Y	-34.24%
Book/sh	6.33	P/B	2.91	EPS next Y	-15.73%	ROA	-29.79%	Short Interest	7.44M	Perf Year	-25.43%
Cash/sh	6.39	P/C	2.88	EPS next 5Y	-18.00%	ROE	-32.04%	52W Range	13.30 - 30.03	Perf YTD	-18.13%
Dividend Est.	-	P/FCF	-	EPS past 5Y	19.02%	ROI	-28.73%	52W High	-38.66%	Beta	0.83
Dividend TTM	-	Quick Ratio	19.99	Sales past 5Y	0.00%	Gross Margin	-	52W Low	38.50%	ATR (14)	1.48
Dividend Ex-Date	-	Current Ratio	19.99	EPS Y/Y TTM	12.85%	Oper. Margin	-	RSI (14)	47.87	Volatility	7.54% 8.69%
Employees	62	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.11	Target Price	37.88
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	1.30%	Payout	-	Rel Volume	1.88	Prev Close	18.63
Sales Surprise	-	EPS Surprise	10.61%	Sales Q/Q	-	Earnings	Mar 13 AMC	Avg Volume	272.21K	Price	18.42
SMA20	1.19%	SMA50	-4.52%	SMA200	-19.34%	Trades		Volume	511,962	Change	-1.13%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-13-24	Initiated	BTIG Research	Buy	$42
Sep-09-24	Initiated	H.C. Wainwright	Buy	$37
Jun-11-24	Initiated	Robert W. Baird	Outperform	$32
Apr-09-24	Initiated	Mizuho	Buy	$34
Mar-29-23	Initiated	Jefferies	Buy	$27

Apr-22-25 02:54PM	Enliven Therapeutics: Awaiting Additional Trial Data (Seeking Alpha) +10.79%
Apr-02-25 04:03PM	Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting (PR Newswire) +5.19%
Mar-13-25 04:05PM	Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update (PR Newswire)
Feb-25-25 04:05PM	Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference (PR Newswire) -5.71%
Jan-31-25 07:00AM	Biotech walks a 'tightrope' amid unclear funding, regulations (Yahoo Finance Video)
04:05PM	Loading…
Nov-13-24 04:05PM	Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update (PR Newswire) -5.04%
Nov-07-24 04:05PM	Enliven Therapeutics to Present at the Jefferies London Healthcare Conference (PR Newswire)
Oct-18-24 04:38PM	Why this largely unknown company is one analyst's top biotech pick (Yahoo Finance Video)
Oct-04-24 09:00AM	FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket (PR Newswire) +7.92%
Sep-30-24 04:52AM	Enliven Therapeutics ELVN-001 shows promise in Phase I CML trial (Clinical Trials Arena) +5.84%
Sep-28-24 09:35AM	Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia (GlobeNewswire)
Sep-26-24 08:50AM	Here's Why Momentum in Enliven Therapeutics, Inc. (ELVN) Should Keep going (Zacks)
Sep-18-24 04:05PM	Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML (GlobeNewswire) +6.02%
Sep-09-24 02:05PM	Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst (Benzinga) +7.28%
Sep-04-24 09:55AM	Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High? (Zacks)
09:55AM	Loading…
Aug-16-24 09:55AM	Wall Street Analysts Think Enliven Therapeutics, Inc. (ELVN) Could Surge 43.04%: Read This Before Placing a Bet (Zacks)
Aug-13-24 04:05PM	Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update (GlobeNewswire)
May-29-24 04:05PM	Enliven Therapeutics to Present at Two Upcoming Investor Conferences (GlobeNewswire) -8.14% +5.67%
May-20-24 05:06PM	Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing (MT Newswires)
May-14-24 10:54PM	ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
05:01PM	Enliven Therapeutics Q1 Loss Narrows (MT Newswires)
04:05PM	Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update (GlobeNewswire)
Apr-19-24 03:03PM	MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-11-24 03:44PM	Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program (Benzinga) +20.18%
07:55AM	Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia (GlobeNewswire)
Apr-09-24 04:05PM	Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors (GlobeNewswire)
Mar-28-24 04:05PM	Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024 (GlobeNewswire) -5.58% +7.45%
Mar-23-24 01:51AM	Enliven Therapeutics Inc Director Rahul Ballal Sells 13,278 Shares (GuruFocus.com)
Mar-19-24 08:30AM	Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates (GlobeNewswire) +38.77%
Mar-14-24 09:53PM	ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -5.95%
04:05PM	Loading…
04:05PM	Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-27-24 04:05PM	Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference (GlobeNewswire)
Jan-03-24 09:01AM	Enliven Therapeutics Inc CFO Benjamin Hohl Sells 11,870 Shares (GuruFocus.com)
Nov-09-23 04:05PM	Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) -7.97%
Aug-17-23 06:40AM	7 A-Rated Biotech Stocks for Your August Buy List (InvestorPlace) +6.00%
Aug-10-23 04:05PM	Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-31-23 04:55PM	Enliven Therapeutics to Present at Two Upcoming Investor Conferences (GlobeNewswire) +8.85%
May-11-23 04:05PM	Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Mar-24-23 06:30AM	7 Biotech Stocks Sitting in the Sweet Spot (InvestorPlace)

Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headquartered in Boulder, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Patel Anish	CHIEF OPERATING OFFICER	May 07 '25	Sale	18.39	6,667	122,579	309,976	May 09 06:48 PM
Patel Anish	Officer	May 07 '25	Proposed Sale	19.69	6,667	131,273		May 07 04:11 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	May 01 '25	Sale	20.07	5,030	100,966	992,658	May 05 06:43 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	May 02 '25	Sale	20.01	2,470	49,424	990,188	May 05 06:43 PM
Kintz Samuel	PRESIDENT AND CEO	May 01 '25	Sale	20.08	5,330	107,007	980,062	May 05 06:42 PM
Kintz Samuel	PRESIDENT AND CEO	May 02 '25	Sale	20.00	2,170	43,409	977,892	May 05 06:42 PM
Lyssikatos Joseph P	Officer	May 01 '25	Proposed Sale	18.94	7,500	142,050		May 01 04:03 PM
Kintz Samuel	Officer	May 01 '25	Proposed Sale	18.94	7,500	142,050		May 01 04:02 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Apr 28 '25	Option Exercise	2.48	3,250	8,060	26,250	Apr 30 06:59 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Apr 28 '25	Sale	18.69	3,250	60,738	23,000	Apr 30 06:59 PM
Hohl Benjamin	Officer	Apr 28 '25	Proposed Sale	18.21	3,250	59,182		Apr 28 04:19 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Apr 21 '25	Sale	16.07	5,000	80,366	997,688	Apr 23 05:09 PM
Kintz Samuel	PRESIDENT AND CEO	Apr 17 '25	Sale	16.42	5,000	82,096	985,392	Apr 21 05:55 PM
Lyssikatos Joseph P	Officer	Apr 21 '25	Proposed Sale	16.53	5,000	82,650		Apr 21 04:28 PM
Kintz Samuel	Officer	Apr 17 '25	Proposed Sale	16.07	5,000	80,350		Apr 17 04:19 PM
Patel Anish	Member of immediate family of	Apr 14 '25	Proposed Sale	16.51	2,010	33,185		Apr 14 04:54 PM
Patel Anish	Member of immediate family of	Apr 14 '25	Proposed Sale	16.51	2,010	33,185		Apr 14 04:48 PM
Patel Anish	CHIEF OPERATING OFFICER	Apr 07 '25	Sale	18.04	6,667	120,269	316,643	Apr 09 04:25 PM
Patel Anish	Officer	Apr 07 '25	Proposed Sale	18.69	6,667	124,606		Apr 07 04:09 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Mar 27 '25	Option Exercise	2.48	3,250	8,060	26,250	Mar 31 07:37 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Mar 27 '25	Sale	21.33	3,250	69,321	23,000	Mar 31 07:37 PM
Hohl Benjamin	Officer	Mar 27 '25	Proposed Sale	20.58	4,250	87,465		Mar 27 04:01 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Mar 24 '25	Option Exercise	2.48	1,000	2,480	24,000	Mar 26 07:37 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Mar 24 '25	Sale	22.50	1,000	22,504	23,000	Mar 26 07:37 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Mar 19 '25	Sale	20.61	12,500	257,575	1,002,688	Mar 21 05:49 PM
Kintz Samuel	PRESIDENT AND CEO	Mar 17 '25	Sale	20.83	12,500	260,320	990,392	Mar 19 05:42 PM
Lyssikatos Joseph P	Officer	Mar 19 '25	Proposed Sale	20.28	12,500	253,500		Mar 19 04:18 PM
Kintz Samuel	Member of immediate family of	Mar 18 '25	Proposed Sale	21.04	21,531	453,012		Mar 18 04:14 PM
Kintz Samuel	Member of immediate family of	Mar 18 '25	Proposed Sale	21.04	21,531	453,012		Mar 18 04:06 PM
Kintz Samuel	Officer	Mar 17 '25	Proposed Sale	20.74	12,500	259,250		Mar 17 04:14 PM
Patel Anish	Member of immediate family of	Mar 17 '25	Proposed Sale	20.74	2,500	51,850		Mar 17 04:08 PM
Patel Anish	Member of immediate family of	Mar 17 '25	Proposed Sale	20.74	2,500	51,850		Mar 17 04:04 PM
Patel Anish	CHIEF OPERATING OFFICER	Mar 07 '25	Sale	21.44	6,667	142,936	323,310	Mar 11 05:18 PM
Patel Anish	Officer	Mar 07 '25	Proposed Sale	21.46	6,667	143,074		Mar 07 04:18 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Mar 04 '25	Option Exercise	2.48	10,000	24,800	23,000	Mar 06 06:02 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Feb 27 '25	Option Exercise	2.48	3,250	8,060	16,250	Mar 03 08:07 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Feb 27 '25	Sale	20.41	3,250	66,327	13,000	Mar 03 08:07 PM
Hohl Benjamin	Officer	Feb 27 '25	Proposed Sale	20.28	4,250	86,190		Feb 27 04:10 PM
Patel Anish	Member of immediate family of	Feb 14 '25	Proposed Sale	21.50	2,500	53,750		Feb 14 05:02 PM
Patel Anish	Member of immediate family of	Feb 14 '25	Proposed Sale	21.50	2,500	53,750		Feb 14 04:17 PM
Patel Anish	CHIEF OPERATING OFFICER	Feb 07 '25	Sale	21.93	6,667	146,206	329,977	Feb 10 05:32 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Feb 05 '25	Option Exercise	2.48	1,000	2,480	14,000	Feb 07 07:06 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Feb 05 '25	Sale	22.52	1,000	22,524	13,000	Feb 07 07:06 PM
Patel Anish	Officer	Feb 07 '25	Proposed Sale	22.47	6,667	149,807		Feb 07 04:02 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jan 27 '25	Option Exercise	2.48	3,250	8,060	16,250	Jan 29 07:21 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jan 27 '25	Sale	21.59	3,250	70,178	13,000	Jan 29 07:21 PM
Hohl Benjamin	Officer	Jan 27 '25	Proposed Sale	21.86	4,250	92,905		Jan 27 04:37 PM
Patel Anish	Member of immediate family of	Jan 14 '25	Proposed Sale	22.07	2,500	55,175		Jan 14 04:06 PM
Patel Anish	Member of immediate family of	Jan 14 '25	Proposed Sale	22.07	2,500	55,175		Jan 14 04:01 PM
Patel Anish	CHIEF OPERATING OFFICER	Jan 07 '25	Option Exercise	1.81	21,700	39,264	21,700	Jan 10 05:31 PM
Patel Anish	CHIEF OPERATING OFFICER	Jan 07 '25	Sale	24.18	21,700	524,697	0	Jan 10 05:31 PM
Patel Anish	CHIEF OPERATING OFFICER	Jan 07 '25	Sale	24.17	6,667	161,171	336,644	Jan 10 05:31 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Dec 13 '24	Option Exercise	2.48	13,000	32,240	13,000	Jan 07 04:43 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jan 03 '25	Option Exercise	2.48	1,000	2,480	14,000	Jan 07 04:43 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jan 03 '25	Sale	25.04	1,000	25,039	13,000	Jan 07 04:43 PM
Patel Anish	Officer	Jan 07 '25	Proposed Sale	24.07	28,367	682,794		Jan 07 04:21 PM
Hohl Benjamin	Officer	Jan 03 '25	Proposed Sale	23.90	1,000	23,900		Jan 03 04:05 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Dec 27 '24	Option Exercise	2.48	3,350	8,308	3,350	Dec 31 05:18 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Dec 30 '24	Option Exercise	2.48	900	2,232	900	Dec 31 05:18 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Dec 27 '24	Sale	22.15	3,350	74,219	0	Dec 31 05:18 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Dec 30 '24	Sale	22.51	900	20,255	0	Dec 31 05:18 PM
Hohl Benjamin	Officer	Dec 27 '24	Proposed Sale	22.71	4,250	96,518		Dec 27 04:33 PM
Patel Anish	Member of immediate family of	Dec 16 '24	Proposed Sale	23.15	2,500	57,875		Dec 16 04:30 PM
Patel Anish	Member of immediate family of	Dec 16 '24	Proposed Sale	23.15	2,500	57,875		Dec 16 04:15 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Nov 27 '24	Option Exercise	2.48	5,250	13,020	5,250	Dec 02 05:18 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Nov 27 '24	Sale	24.89	5,250	130,688	0	Dec 02 05:18 PM
Patel Anish	Member of immediate family of	Nov 15 '24	Proposed Sale	24.92	17,500	436,100		Nov 15 04:35 PM
Patel Anish	Member of immediate family of	Nov 15 '24	Proposed Sale	24.92	17,500	436,100		Nov 15 04:28 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 28 '24	Option Exercise	2.48	6,250	15,500	6,250	Oct 30 06:04 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 28 '24	Sale	28.56	6,250	178,485	0	Oct 30 06:04 PM
Patel Anish	CHIEF OPERATING OFFICER	Oct 18 '24	Sale	30.00	716	21,483	343,311	Oct 22 04:23 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Oct 18 '24	Sale	30.00	847	25,413	1,015,188	Oct 22 04:22 PM
Kintz Samuel	PRESIDENT AND CEO	Oct 18 '24	Sale	30.00	924	27,723	1,002,892	Oct 22 04:21 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 18 '24	Option Exercise	2.48	814	2,019	814	Oct 22 04:19 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 18 '24	Sale	30.00	814	24,422	0	Oct 22 04:19 PM
Heyman Richard A.	Director	Oct 18 '24	Sale	30.00	817	24,512	123,673	Oct 22 04:18 PM
Heyman Richard A.	Director	Oct 18 '24	Sale	30.00	753	22,592	27,165	Oct 22 04:18 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Oct 18 '24	Option Exercise	2.48	816	2,024	816	Oct 22 04:17 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Oct 18 '24	Sale	30.00	816	24,482	0	Oct 22 04:17 PM
Patel Anish	Officer	Oct 18 '24	Proposed Sale	28.02	50,000	1,401,000		Oct 18 06:42 PM
Lyssikatos Joseph P	Officer	Oct 18 '24	Proposed Sale	28.02	65,000	1,821,300		Oct 18 05:42 PM
Heyman Richard A.	Director	Oct 18 '24	Proposed Sale	28.02	1,566	43,879		Oct 18 05:27 PM
Kintz Samuel	Officer	Oct 18 '24	Proposed Sale	28.02	91,123	2,553,266		Oct 18 05:17 PM
Heyman Richard A.	Director	Oct 18 '24	Proposed Sale	28.02	12,165	340,863		Oct 18 05:10 PM
Hohl Benjamin	Officer	Oct 18 '24	Proposed Sale	28.02	13,000	364,260		Oct 18 05:00 PM
Collins Helen Louise	Officer	Oct 18 '24	Proposed Sale	28.02	25,000	700,500		Oct 18 04:57 PM
Heyman Richard A.	Director	Oct 15 '24	Sale	27.67	1,270	35,143	124,490	Oct 17 05:06 PM
Heyman Richard A.	Director	Oct 15 '24	Proposed Sale	27.75	1,270	35,242		Oct 15 04:38 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Oct 09 '24	Sale	28.16	37,878	1,066,561	1,016,035	Oct 10 08:39 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Oct 08 '24	Sale	27.97	13,267	371,024	1,053,913	Oct 10 08:39 PM
Kintz Samuel	PRESIDENT AND CEO	Oct 09 '24	Sale	28.15	16,710	470,405	1,003,816	Oct 10 08:38 PM
Kintz Samuel	PRESIDENT AND CEO	Oct 08 '24	Sale	27.96	13,267	370,929	1,020,526	Oct 10 08:38 PM
Ballal Rahul D.	Director	Oct 08 '24	Option Exercise	14.10	10,420	146,925	32,761	Oct 10 08:36 PM
Ballal Rahul D.	Director	Oct 08 '24	Sale	28.17	10,420	293,557	22,341	Oct 10 08:36 PM
Lyssikatos Joseph P	Officer	Oct 09 '24	Proposed Sale	28.01	12,000	336,120		Oct 09 04:27 PM
Kintz Samuel	Officer	Oct 09 '24	Proposed Sale	28.01	12,000	336,120		Oct 09 04:16 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Oct 04 '24	Sale	27.51	7,522	206,937	1,069,887	Oct 08 06:58 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Oct 07 '24	Sale	27.61	2,707	74,727	1,067,180	Oct 08 06:58 PM
Kintz Samuel	PRESIDENT AND CEO	Oct 04 '24	Sale	27.51	12,206	335,792	1,036,523	Oct 08 06:57 PM
Kintz Samuel	PRESIDENT AND CEO	Oct 07 '24	Sale	27.50	2,730	75,075	1,033,793	Oct 08 06:57 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ELVN

Enliven Therapeutics Inc

Upgrade your FINVIZ experience